Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin

Peritoneal Dialysis International

Volumn 23, Issue 4, 2003, Pages 362-367

  Ahn, Curie ^a   Oh, Kook Hwan ^b   Kim, Kiwon ^a   Lee, Kyung Yi ^a   Lee, Jung Geon ^c   Oh, Myung Don ^a   Kim, Yonsu ^a   Han, Jin Suk ^a   Kim, Suhnggwon ^a   Lee, Jung Sang ^a   Jang, In Jin ^a   Shin, Sang Goo ^a  

^a Seoul National University   (South Korea)

^b Hallym University   (South Korea)

^c Eulji University School of Medicine   (South Korea)

Author keywords

Isoniazid; Pharmacokinetics; Pyrazinamide; Rifampin; Tuberculosis

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; FEMALE; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG TUBERCULOSIS; MAINTENANCE THERAPY; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; PERITONEAL FLUID; PRIORITY JOURNAL; TUBERCULOSIS; TUBERCULOUS PERITONITIS;

ADULT; ANTITUBERCULAR AGENTS; ASCITIC FLUID; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PYRAZINAMIDE; RIFAMPIN;

EID: 10744233708     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Pradhan RP, Katz LA, Nidus BD, Matalon R, Eisinger RP. Tuberculosis in dialyzed patients. JAMA 1974; 229:798-800.
2. Chou KJ, Fang HC, Bai KJ, Hwang SJ, Yang WC, Chung HM. Tuberculosis in maintenance dialysis patients. Nephron 2001; 88:138-43.
3. Lui SL, Tang S, Li FK, Choy BY, Chan TM, Lo WK, et al. Tuberculosis infection in Chinese patients undergoing continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2001; 38:1055-60.
4. Quantrill SJ, Woodhead AM, Bell CE, Hutchison AJ, Gokal R. Peritoneal tuberculosis in patients receiving continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2001; 16:1024-7.
5. Lui SL, Lo CY, Choy BY, Chan TM, Lo WK, Cheng IK. Optimal treatment and long-term outcome of tuberculous peritonitis complicating continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 28:747-51.
6. Cheng IK, Chan PC, Chan MK. Tuberculous peritonitis complicating long-term peritoneal dialysis. Report of 5 cases and review of the literature. Am J Nephrol 1989; 9:155-61.
7. Ahijado F, Luno J, Soto I, Gallego E, Junco E, Polo JR, et al. Tuberculous peritonitis in patients on CAPD. Contrib Nephrol 1991; 89:79-86.
8. Hwang YS, Ahn JH, Lee TW, Ihm CG, Kim MJ. 3 cases of tuberculous peritonitis complicating long term CAPD. Korean Journal of Nephrology 1991; 10:245-9.
9. Lee WK, Park SB, Kim HC. Tuberculous peritonitis complicating continuous ambulatory peritoneal dialysis. Korean Journal of Nephrology 1990; 9:90-5.
10. Woo J, Leung A, Chan K, Lai KN, Teoh R. Pyrazinamide and rifampicin regimens for patients on maintenance dialysis. Int J Artif Organs 1988; 11:181-5.
11. Olson WA, Dayton PG, Israili ZH, Pruitt AW. Spectrophotofluorometric assay for isoniazid and acetyl-isoniazid in plasma adapted to pediatric studies. Clin Chem 1977; 23:745-8.
12. Jamaluddin ABM, Sarwar G, Rahim MA, Rahman MK. High-performance liquid chromatographic assay of rifampicin in human serum. J Chromatogr 1990; 525: 495-7.
13. Yamamoto T, Moriwaki Y, Takahashi S, Hada T, Higashino K. Rapid and simultaneous determination of pyrazinamide and its major metabolites in human plasma by high-performance liquid chromatography. J Chromatogr 1987; 413:342-6.
14. Ellard GA. Chemotherapy of tuberculosis for patients with renal impairment. Nephron 1993; 64:169-81.
15. Kim DJ, Kim SK, Lee JS, Han YC, Lee MH, Lee SH, et al. Pharmacokinetic changes of pyrazinamide in patients with impaired renal function during hemodialysis. Korean J Intern Med 1986; 31:13-19.
16. Holdiness MR. Cerebrospinal fluid pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1985; 10:532-4.
17. Ellard GA. Absorption, metabolism and excretion of pyrazinamide in man. Tubercle 1969; 50:144-58.
18. Hong Kong Tuberculosis Treatment Services/British Medical Research Council. Adverse reactions to short course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong. Tubercle 1976; 57:81-95.
19. Stamatakis G, Montes C, Trouvin JH, Farinotti R, Fessi H, Kenouch S, et al. Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure. Clin Nephrol 1988; 30:230-4.
20. Lacroix C, Hoang TP, Nouveau J, Guyonnaud C, Laine G, Duwoos H, et al. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol 1989; 36:395-400.
21. Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH. Tuberculosis in patients with end-stage renal disease. Am J Med 1980; 68:59-65.
22. McEvoy GK. AHFS Drug Information. Bethesda, MD: the American Society of Health-System Pharmacists, Inc; 2001.
23. Paiva A, Cirugeda A, Bajo MA, Selgas R. Successful treatment of peritonitis in CAPD with intraperitoneal rifampin. Perit Dial Int 1998; 18:543-4.